Local view for "http://wifo5-04.informatik.uni-mannheim.de/drugbank/resource/drugs/DB04865"

Predicate	Value (sorted: default)
rdfs:label	"Homoharringtonine"
rdf:type	drugbank:drugs
drugbank:description	"Homoharringtonine, AKA HHT or omacetaxine mepesuccinate, is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Homoharringtonine is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, homoharringtonine received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, homoharringtonine received Orphan Drug status from the FDA for the treatment of CML. In November 2006, homoharringtonine, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, homoharringtonine was marketed under the brand name Synriboâ„¢ and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. "
drugbank:drugCategory	drugcategory:Angiogenesis Inhibitors drugcategory:Antineoplastic Agents drugcategory:Antineoplastic Agents, Phytogenic
drugbank:interactsWith	drug:Natalizumab drug:Pimecrolimus drug:Warfarin drug:Tacrolimus drug:Acetylsalicylic acid drug:Ibuprofen drug:Tofacitinib
owl:sameAs	drug:Natalizumab drug:Pimecrolimus drug:Warfarin drug:Tacrolimus drug:Acetylsalicylic acid drug:Ibuprofen drug:Tofacitinib

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines3/drugbank_small.nt

The resource appears as object in 14 triples

Context graph